Soraya Puglisi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3776248/publications.pdf

Version: 2024-02-01

62	800	471509 17	580821 25
papers	citations	h-index	g-index

66	66	66	773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: from histopathological features to clinical presentations. Pulmonology, 2022, 28, 333-344.	2.1	17
2	Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas. Frontiers in Endocrinology, 2022, 13, 833514.	3.5	6
3	First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.. Journal of Clinical Oncology, 2022, 40, 1-1.	1.6	6
4	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	11.4	55
5	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushingâ€™s syndrome. Pituitary, 2021, 24, 104-115.	2.9	20
6	What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study. Journal of Endocrinological Investigation, 2021, 44, 865-872.	3.3	3
7	Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence. Pituitary, 2021, 24, 483-491.	2.9	5
8	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. Life, 2021, 11, 266.	2.4	6
9	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 2021, 11, 269.	2.5	14
10	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. Journal of the Endocrine Society, 2021, 5, A166-A167.	0.2	16
11	Adrenal Hyperplasia as Possible Predictor of Mortality in Patients Admitted for Suspected SARS-Cov-2 Infection: A Prospective Study. Journal of the Endocrine Society, 2021, 5, A76-A76.	0.2	0
12	Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, .	1.2	2
13	Adrenocortical Cancer. , 2021, , 319-326.		0
14	Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies. Cancers, 2021, 13, 5255.	3.7	13
15	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 2021, 12, 738848.	3.5	36
16	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
17	Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Frontiers in Endocrinology, 2021, 12, 793262.	3.5	7
18	Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e973-e981.	3.6	69

#	Article	IF	Citations
19	Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. Cancers, 2020, 12, 2615.	3.7	24
20	May an adrenal incidentaloma change its nature?. Journal of Endocrinological Investigation, 2020, 43, 1301-1307.	3.3	1
21	New perspectives for mitotane treatment of adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101415.	4.7	49
22	Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma. Cancers, 2020, 12, 639.	3.7	16
23	Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide. Frontiers in Endocrinology, 2020, 11, 28.	3.5	3
24	Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. European Radiology, 2020, 30, 6958-6964.	4.5	10
25	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	3.7	28
26	Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. Cells, 2020, 9, 885.	4.1	2
27	Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population?. European Journal of Endocrinology, 2020, 183, D1-D13.	3.7	19
28	Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 485-487.	1.2	7
29	Is Follow-up of Adrenal Incidentalomas Always Mandatory?. Endocrinology and Metabolism, 2020, 35, 26.	3.0	6
30	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	2.4	31
31	Determination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patients. European Journal of Internal Medicine, 2019, 68, 66-70.	2.2	3
32	Mitotane: new facts for an old drug. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 145-151.	1.4	1
33	First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. Growth Hormone and IGF Research, 2019, 45, 17-19.	1.1	2
34	Hypertension and Acromegaly. Endocrinology and Metabolism Clinics of North America, 2019, 48, 779-793.	3.2	20
35	GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. Journal of Endocrinological Investigation, 2019, 42, 825-831.	3.3	16
36	Adrenocortical Carcinoma: Diagnosis and Therapy. , 2019, , 308-316.		0

#	Article	IF	Citations
37	Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. European Journal of Endocrinology, 2019, 180, 387-396.	3.7	38
38	SAT-365 Prevalence and Clinical Features of Adrenal Incidentalomas: A Prospective Study in an Unselected Population. Journal of the Endocrine Society, 2019, 3, .	0.2	0
39	Adrenocortical Carcinoma with Hypercortisolism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 395-407.	3.2	29
40	How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of Endocrinological Investigation, 2018, 41, 575-581.	3.3	18
41	Adrenal Incidentalomas. , 2018, , 303-307.		0
42	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. Expert Review of Anticancer Therapy, 2018, 18, 1125-1133.	2.4	34
43	Preoperative treatment with metyrapone in patients with Cushingâ€™s syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Connections, 2018, 7, 1227-1235.	1.9	13
44	Autonomous hypercortisolism: definition and clinical implications. Minerva Endocrinologica, 2018, 44, 33-42.	1.8	9
45	Effects of mitotane on the hypothalamicâ€“pituitaryâ€“adrenal axis in patients with adrenocortical carcinoma. European Journal of Endocrinology, 2017, 177, 361-367.	3.7	25
46	Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1872-1879.	3.6	34
47	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine, 2016, 54, 762-767.	2.3	30
48	Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas. PLoS ONE, 2016, 11, e0162437.	2.5	13
49	Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine, 2014, 47, 206-12.	2.3	16
50	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. Clinical Endocrinology, 2014, 81, 249-253.	2.4	21
51	The management of post-operative recurrences in patients with adrenocortical carcinoma (ACC): The experience of San Luigi Hospital. Endocrine Abstracts, 0, , .	0.0	0
52	Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	1
53	Incidental detection of adrenal hyperplasia and mortality in patients with suspected SARS-CoV-2 Infection. Endocrine Abstracts, 0, , .	0.0	0
54	Preoperative treatment with metyrapone in patient with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Abstracts, 0, , .	0.0	1

#	Article	IF	Citations
55	Effects of cyberknife radiotherapy treatment of pituitary adenomas. Endocrine Abstracts, 0, , .	0.0	0
56	Assessment of the hypothalamic pituitary adrenal axis in patients receiving adjuvant mitotane treatment after radical resection of adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
57	Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients. Endocrine Abstracts, 0, , .	0.0	0
58	Outcome of adjuvant mitotane therapy in patients with adrenocortical carcinoma: the experience of San Luigi Gonzaga Hospital. Endocrine Abstracts, 0, , .	0.0	0
59	Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
60	How do sex and BMI affect glucocorticoid treatment in adrenal insufficiency?. Endocrine Abstracts, 0, , .	0.0	0
61	Management of mitotane for advanced adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
62	Effects of different therapeutic approaches on cardiovascular risk in patients with acromegaly: Results of a multicentric study. Endocrine Abstracts, 0, , .	0.0	0